The Treatment and Prevention study (TAP) is a world-first clinical trial of DAA treatment for a group of people who inject drugs (PWID). Individuals are treated for hepatitis C together with people with whom they inject drugs, in order to prevent reinfection after successful treatment.
TAP study participants are asked how many people they have injected with (same time and place) over the past six months and how many in the past month. Despite often reporting injecting with many people, participants have mostly only brought a couple of friends into the study.
The study aimed to answer the following questions:
This study involved a mixed method approach.